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Highlights 
 Women could benefit from lowering the starting age of regular breast cancer 
screening.  
 More small tumours will be detected and more breast cancer deaths will be averted at 
reasonable additional costs if screening starts before the age of 50 years. 
 Introducing two additional screening rounds to the current biennial breast cancer 
screening in the Netherlands is justifiable from a cost-effectiveness and benefit–harms 
point of view. 
 
Abstract 
Background 
Because the incidence of breast cancer increases between 45 and 50 years of age, a 
reconsideration is required of the current starting age (typically 50 years) for routine 
mammography. Our aim was to evaluate the quantitative benefits, harms, and cost-
effectiveness of lowering the starting age of breast cancer screening in the Dutch general 
population. 
Methods 
Economic modelling with a lifelong perspective compared biennial screening for women 
aged 48–74 years and for women aged 46–74 years with the current Dutch screening 
programme, which screen women between the ages of 50 and 74 years. Tumour deaths 
prevented, years of life saved (YOLS), false-positive rates, radiation-induced tumours, costs 
and incremental cost-effectiveness ratios (ICERs) were evaluated. 
Results 
Starting the screening at 48 instead of 50 years of age led to increases in: the number of small 
tumours detected (4.0%), tumour deaths prevented (5.6%), false positives (9.2%), YOLS 
(5.6%), radiation-induced tumours (14.7%), and costs (4.1%). Starting the screening at 46 
instead of 48 years of age increased the number of small tumours detected (3.3%), tumour 
deaths prevented (4.2%), false positives (8.8%), YOLS (3.7%), radiation-induced tumours 
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(15.2%), and costs (4.0%). The ICER was €5,600/YOLS for the 48-74 scenario and 
€5,600/YOLS for the 46-74 scenario. 
Conclusions 
Women could benefit from lowering the starting age of screening as more breast cancer 
deaths would be averted. Starting regular breast cancer screening earlier is also cost-effective. 
As the number of additional expected harms is relatively small in both the scenarios 
examined, and the difference in ICERs is not large, introducing two additional screening 
rounds is justifiable. 
 
Keywords: breast neoplasm; mass screening; mammography; age; cost-effectiveness 
analysis; computer simulation 
 
Introduction 
Breast cancer screening has been implemented in many European countries to detect breast 
cancer at an early stage and decrease breast cancer mortality. In these programmes, usually 
the age of 50 is considered optimal for starting regular screening due to the increasing 
incidence of the disease afterwards [1]. There are, however, some countries (United 
Kingdom, Czech Republic) and regions (e.g. in Sweden and Italy) that invite women younger 
than 50 years to be screened despite the controversy in the benefit-harm balance [1, 2]. 
Arguments in favour of lowering the starting age of screening are based on the potential 
breast cancer specific mortality decrease for women as there is evidence of an increased 
incidence of breast cancer above the age of 40 and more prominently between 45 and 50 
years, and there is a great potential number of years of life gained for deaths averted [3]. 
Results from the United Kingdom Age Trial [4] suggest that regular mammographic 
screening in the age group 40-49 could reduce the risk of dying from breast cancer (relative 
risk (RR) 0.88 (95% confidence interval (CI) 0.74–1.04), although the reduction was less 
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pronounced as compared to results from meta-analyses for older age groups [5-6]. On the 
other hand, there are also studies showing that potential harms as overdiagnosed breast 
cancers [7], radiation-induced breast cancer deaths [8, 9], false positive test results [10–15], 
unnecessary biopsies [11, 12], and costs of false positive biopsies [16] accompany regular 
screening, though their estimated numbers varied largely. Such potential harms have been 
considered to outweigh the benefits of regular screening for women 40-49 years old and thus 
regular breast cancer screening in this age group is generally not recommended [17]. 
There are a number of recent modelling studies [7, 8, 10–15] which tried to balance the 
expected benefits and harms of breast cancer screening but these evaluations were partial, i.e. 
focused only on mortality reduction, radiation-induced tumours and tumour deaths, or 
overdiagnosis and only two of them analysed the Dutch setting [7, 8]. The most recent study 
focused on the cost-effectiveness of digital mammography screening before the age of 50 in 
the Netherlands and concluded that additional screening between age 40 and 49 was cost-
effective, however, their model only considered age as a risk factor for breast cancer and did 
not incorporate other factors as breast density which is important in younger age groups [18]. 
Therefore, in the current analysis we performed a comprehensive evaluation regarding the 
proper balance of harms and benefits of regular breast cancer screening starting from a 
younger age, including breast density variation as a function of age. The aim of our study was 
to evaluate the quantitative benefits, harms, and cost-effectiveness of lowering the starting 
age of breast cancer screening in the Dutch general population given the already available 
biennial screening among women aged 50-74. The following outcomes were considered: 
tumour deaths prevented, years of life saved (YOLS), number of false positives, radiation-
induced tumours, costs and cost-effectiveness. Qualitative outcomes (such as quality of life) 
were not included. 
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Methods 
This study was reported according to the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement [19]. We applied the Simulation Model on 
Radiation Risk and breast cancer Screening (SiMRiSc) in the current analysis. The model 
was previously published and externally validated in women with BRCA mutations [20–22]. 
For the purpose of this analysis, the SiMRiSc model was extended by including a breast 
density parameter (Table 1) and externally validated (Table 2) for the general population of 
women by comparing the outcomes to empirical data from the Dutch national screening 
program. As this model was restricted to invasive breast cancer only, ductal carcinoma in situ 
(DCIS) was not included. 
The current breast cancer screening scheme in the Netherlands was included: biennial 
population screening in women aged 50-74 years as a reference scenario. Scenarios were 
developed for two alternative screening regimens with earlier starting ages: biennial 
screening from 48 to 74 years and from 46 to 74 years. The outcomes of the model consisted 
of potential benefits: tumour deaths prevented, YOLS; and potential harms of screening: 
number of false positives and radiation-induced tumours. 
 
Description of the model and its components 
SiMRiSc is a micro-simulation Markov model (Figure 1). An extensive description of the 
model can be found in previous publications [20–23]. Women were simulated during their 
lifetime taking into account their life expectancy, chance of developing a tumour, tumour 
growth and survival from breast cancer, breast density and mammographic sensitivity and 
specificity, and risk of tumour induction due to diagnostic radiation. If a tumour was present 
at the screening moment, the chance of detection was dependent on the mammographic 
sensitivity. If the tumour was found, either by screening or self-detection, the woman was 
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removed from the simulation and the breast cancer specific death age of the woman was 
calculated based on the life expectancy after breast cancer diagnosis depending on the tumour 
size at clinical detection. 
The model parameters are presented in Table 1. In the simulation, every woman was given a 
predetermined natural death age which was sampled from the life expectancy in the 
Netherlands [20]. The breast cancer incidence rate was sampled to assign an individual 
probability to develop breast cancer during the lifetime of the women and the age at which 
the tumour would be clinically detected [24]. A systematic literature search was performed to 
estimate the parameters in the tumour growth model and the tumour size at clinical (self-) 
detection. The history of the tumour was calculated by applying an exponential growth model 
with an age-dependent tumour volume doubling time sampled from a population log-normal 
distribution. The preclinical period of the tumour was defined as the time from which the 
tumour size was larger than the minimal detection threshold for mammography (5mm) until 
the time of clinical detection without screening [25]. The specificity of mammography was 
based on a single RCT which was considered the best source for mammographic specificity 
for the current analysis since the screened women were in the age group 45-69 years [26]. 
Finally, a systematic error was introduced which referred to a fraction of breast cancer cases 
that could not be detected by mammography mainly due to lobular carcinomas, dense breast 
tissue and tumours located close to the thorax wall. Based on expert opinion (RMP), we 
assumed this fraction to be 10%, that is, 10% of all cases that should be detected based on 
tumour volume would not be detected due to their characteristics. 
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Modelling the effect of breast density 
In the model the chance of tumour detection at screening was modelled to be dependent on 
the mammographic sensitivity given the breast density of the woman at certain age. 
Systematic literature searches were performed to find estimates for the distribution of breast 
density in the population and the relation between breast density and mammographic 
sensitivity [27–29]. A meta-analysis based on calculating the weighted average value from 
the reported sample sizes [27–29] was performed to estimate the baseline values and the 95% 
CI for breast density. The same method of meta-analysis was applied for estimating the 
sensitivity of mammography as a function of breast density and age, based on the resulting 
literature [30–38]. 
 
 
Screening scenarios 
Two alternative screening scenarios in which women were subjected to systematic 
mammographic screening were simulated according to different starting ages, i.e. 46 and 48 
years of age. The screening interval was biennial and the end age was set at 74 years. The 
current population breast cancer screening program, i.e. biennial screening in the age group 
50-74 years, was set as a reference scenario and was compared to the alternative scenarios. 
 
 
Expected benefits and harms of regular breast cancer screening 
The results from the model simulations were reported in terms of potential benefits: tumour 
deaths prevented, YOLS; and potential harms of screening: number of false positives and 
radiation-induced tumours. Tumour deaths prevented, YOLS and radiation-induced tumours 
were calculated for both alternative scenarios, biennial screening from 48 to 74 and from 46 
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to 74 with respect to the reference biennial screening from 50 to 74 years of age and for the 
two scenarios compared to each other. 
 
 
Cost-effectiveness analysis 
Only direct medical costs related to screening and treatment of breast cancer were considered 
(Table 3). The costs of a screening test were based on data from the Dutch national screening 
programme, valued in Euros (€) [39]. The costs of a biopsy were based on a study in a similar 
population group [18]. The costs of treatment were dependent on tumour size and based on 
the Dutch cancer registry [20], indexed to 2014 [40]. Incremental cost-effectiveness was 
estimated as the ratio of the incremental costs for screening and the incremental gain in life 
years for the alternative screening strategies compared to no screening. Discounting of 4% for 
costs and 1.5% for health effects (YOLS) was applied according to the Dutch guidelines [41]. 
In order to allow for international comparison, we also applied a discount rate of 3% for both 
costs and effects [42]. 
 
 
Validation of the model 
The model was validated by comparing the point estimates of the simulated outcomes (screen 
detected tumours, tumour size distribution, number of interval cancers, number of false 
positive tests) in the reference scenario to the empirical CI of the observed data from the 
report [38] of the Dutch national screening programme. The number of simulated screen 
detected tumours was compared to the observed incidence separately for the initial and the 
subsequent screening rounds for the age groups 50-54, 55-59, 60-64, 65-69, and 70-74. The 
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simulated results were considered valid when the simulated point estimates fell within the 
estimated empirical CI. 
Sensitivity analyses 
A univariate sensitivity analysis was performed for practical reasons. Since the model has 
been shown to be predominantly sensitive to the input parameters related to lifetime breast 
cancer risk and sensitivity of mammography and to a much lesser extent to the other input 
parameters [22], it was considered that a sampling-based sensitivity analysis where all the 
input parameters were changed at the same time would not provide essentially different 
information. Therefore, univariate sensitivity analyses with minimum and maximum values 
of the 95% CI for the input parameters listed in Table 1 for the entire cohort of 10,000 
women were performed to evaluate the effects of parameter uncertainty. Tornado plots were 
constructed to visualise the impact of parameter uncertainty on the ICER. 
 
Results 
 
Validation of the model 
Table 2 shows the comparison between the numbers of detected breast tumours as simulated 
by the model and as reported in the Dutch national screening programme for the initial and 
the subsequent screening rounds, the tumour size distribution, the number of interval cancers 
and the number of false positive mammograms. 
The model estimated the amount of screen detected tumours for the initial screening round 
very well, but overestimated the number of screen detected tumours in the age group 50-69 
for the subsequent screening rounds. In the remainder age group, the number of simulated 
screen detected tumours fell well within the estimated empirical 95% CI. The proportion of 
small detected tumours was overestimated. The number of the interval cancers and the 
number of false positive mammograms were also overestimated. 
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Expected benefits and harms of regular breast cancer screening, costs and cost-
effectiveness 
The results from the simulations of the three screening scenarios are presented in Table 4. 
The addition of one extra screening round led to increase in the number of small screen 
detected tumours (4.0%), tumour deaths prevented (5.6%), false positives (9.2%), YOLS 
(5.6%), radiation-induced tumours (14.7%), and costs (4.1%) as compared to the reference 
scenario. 
A further increase in the number of small screen detected tumours (3.3%), tumour deaths 
prevented (4.2%), false positives (8.8%), YOLS (3.7%), radiation-induced tumours (15.2%), 
and costs (4.0%) was observed when one extra screening round was added and compared to 
the 48-74 screening scheme. The ICER was €5,600 per YOLS for biennial screening 48-74 as 
compared to no screening and €5,600 per YOLS for biennial screening 46-74 as compared to 
no screening. The ICERs discounted according to the Dutch guidelines were slightly above 
the threshold of €20,000 per YOLS. 
 
Sensitivity analyses 
The sensitivity analyses revealed that the ICERs for the breast cancer screening scenarios 
starting at the age of 46 and 48 years were most sensitive to the uncertainty in the lifetime 
risk of breast cancer, the growth rate of tumours for ages under 50 and the sensitivity of 
mammography (Figure 2a/2b) and were least sensitive to the uncertainty in the specificity of 
mammography, the self-detection diameter and the growth rate of tumours for ages over 70. 
For the 48-74 scenario, the lowest ICER found in the sensitivity analyses was €4,000 per 
YOLS and the highest was €6,100 per YOLS. The lowest ICER found in the sensitivity 
analyses for the scenario 46-74 was €5,100 per YOLS and the highest was €6,100 per YOLS. 
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Discussion 
The aim of this study was to evaluate the benefits, harms, and cost-effectiveness of lowering 
the starting age of breast cancer screening in the Dutch general population given the already 
available biennial screening among women aged 50-74. For the purpose of this analysis, a 
previously published and validated simulation model (SiMRiSc) was extended with a breast 
density input parameter and externally re-validated for the current application. The model 
reproduced the observed data for the first screening round with sufficient validity. The model 
overestimated the number of tumours in the subsequent screening round as well as the 
proportion of small tumours, interval cancers and false positive mammograms. However, 
since we were mainly interested in the relative effect of lowering the starting age of 
screening, we conclude that although the absolute outcome of the validation showed an 
overestimation, the relative outcomes of lowering the starting age of screening were correct. 
Our analysis revealed that starting the regular breast cancer screening at earlier ages could 
result in increased expected benefits in terms of YOLS and tumour deaths prevented, and was 
cost-effective in terms of costs per YOLS. However, the number of expected harms, i.e. false 
positives and radiation-induced tumours also increased. The two alternative scenarios showed 
ICERs that would generally be considered cost-effective with values below €20,000 per 
YOLS. Only the ICERs discounted in accordance with the Dutch guidelines were slightly 
above the threshold of 20,000/YOLS. 
 
Starting breast cancer screening at an earlier age expectedly increased the number of 
prevented tumour deaths due to the increased number of small screen detected tumours which 
could be potentially curable and thus prolonged the survival of breast cancer patients and 
increased their YOLS. However, expanding the lower age limit also increased the potential 
harms of screening in terms of number of radiation-induced tumours and false positives thus 
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affecting negatively the number of YOLS and the mortality reduction from breast cancer. In 
addition, false positive results from screening could increase the distress on patients and bring 
to unnecessary referrals to further testing. The reported ICERs (except for the ones 
discounted according to the Dutch guidelines) were below a commonly referred ceiling 
threshold of €20,000 for cost-effectiveness of preventive care programmes in the Netherlands 
[43]. Our analysis suggested that lowering the screening age for breast cancer seems to show 
slightly declining marginal returns. From a decision-makers’ point of view lowering the 
starting age of breast cancer screening of the general population could be considered as 
adding one and two additional rounds of screening is cost-effective. However, expanding the 
starting age of breast cancer screening even lower would further increase the expected harms 
and thus costs of screening and it is not supported by epidemiological evidence which shows 
prominent increase in the breast cancer incidence above 45 years of age [3]. 
 
Our results are in line and comparable to an earlier modelling study by de Gelder et al [8] 
which also reported increase in prevented tumour deaths with lowering the starting age of 
screening by 4.5% for the 48-74 screening scenario and by 8.5% for the 46-74 one. The 
number of screen detected tumours in our simulations are comparable to the ones reported by 
Sankatsing et al [18]: 3.8% additional screen detected tumours in a screening scenario 
commencing from 48 up to 74 years of age vs. 4.0% additional screen detected tumours in 
our simulations, which resulted in averting 13 breast cancer deaths and adding 10.2% YOLS 
as compared to 123 averted breast cancer deaths and 5.6% increase in YOLS in our scenario. 
False positive screening findings in our analysis are more favourable than the ones from 
Sankatsing et al [18] who reported 18.5% increase in women screened regularly from the age 
of 48 to the age of 74, while we found 9.2% increase in false positives in the same age group. 
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Our results regarding radiation-induced tumours are higher than the ones reported by de 
Gelder et al [8] who revealed that decreasing the starting age of population breast cancer 
screening increased the induced breast cancer incidence and the numbers varied for the 
different scenarios depending on variation of the radiation dose (1-5 mSv), i.e. 5.9-29.6 for 
biennial screening in a simulated cohort of 100 000 women aged 50-74 years, 7.0-35.2 for 
ages 48-74 and 8.3-41.5 for ages 46-74. They concluded that the risk of radiation-induced 
tumours was negligible compared to the number of prevented deaths, however, they assumed 
an average absorbed glandular dose of 1.3 mGy per view (of both breasts) and their 
calculations were based on one-view mammography at subsequent screening rounds [8] 
while in our estimations we utilised the 3 mSv glandular dose which is still state-of-the-art 
for a two-way view mammography screening. The cost-effectiveness ratios of both 
alternative screening scenarios are in line with the findings of other studies which also 
reported the lowering of starting age for breast cancer screening to be cost-effective [18]. 
 
Model simulations predicted the empirical data of the first screening round with sufficient 
validity. Variances between simulated results and empirical 95% CI were observed in the 
number of screen detected tumours in the age group 60-74 for the subsequent screening 
rounds, the size distribution, and in the number of interval cancers and false positives. Since 
the model is most sensitive to the tumour doubling time we calculated that a 15% lower 
tumour doubling time gives a reduction of almost 50% in the number of screen detected 
tumours in the subsequent screening rounds which is well within the empirical 95% CI of the 
observed data. In addition, the proportion of small screen detected tumours (<2cm) reduced 
by 10% whereas the number of interval cancers, due to the decreased tumour doubling time, 
increased even further to 4.5. In the SiMRiSc model women will develop breast cancer at 
specific age and the tumour will grow according to the predefined tumour doubling time, 
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therefore, there will be no length time bias. In addition, the study evaluates the relative effect 
of lowering the starting age of breast cancer screening from 50 to 48 and from 48 to 46, and 
the possible effects of lead time bias will cancel out. A possible explanation for the 
overestimation of the false positive mammograms is that the programme specificity in the 
Netherlands is amongst the highest reported [39]. Another explanation could be the double 
reading which lowers the number of false referrals. However, as seen from the sensitivity 
analyses the specificity of mammography has very little influence on the ICERs (Figure 
2a/2b). The analyses showed that the model is most sensitive to the uncertainty in the lifetime 
risk of breast cancer, the growth rate of tumours for ages under 50 and the sensitivity of 
mammography. However, the highest discounted ICERs found €26,000 per YOLS for the 48-
74 scenario and €27,100 per YOLS for the 46-74 scenario were still slightly above the cost-
effectiveness threshold of €20,000/YOLS. 
 
Our analysis has clearly demonstrated that regular breast cancer screening with earlier 
starting ages could be beneficial for women despite the relevant increase in harms. However, 
recent studies have suggested that the contribution of mass mammography to mortality 
reduction from breast cancer might be overestimated. A drawback of the early detection of 
breast cancer is the diagnosis of cancers which would never become clinically detected 
(overdiagnosis). According to a comprehensive review on European breast cancer screening 
programmes this overdiagnosis accounts on average for 6.5% of all screen detected breast 
cancers [1]. A recent analysis estimated 11% overdiagnosed tumours in the Dutch breast 
cancer screening programme [44]. With the introduction of national breast cancer screening 
programmes, the rate of detection of large tumours decreased in favour of small tumours. 
However, these small tumours are more likely to be overdiagnosed than to become large [45]. 
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Overdiagnosis causes patient harm and overtreatment, increases the costs for the healthcare 
system and decreases the cost-effectiveness of mass breast cancer screening. 
 
In addition, the available adjuvant and targeted therapies have an impact on the mortality 
reduction from breast cancer. The 25-year follow-up of the Canadian National Breast 
Screening Study concluded that in the presence of freely available adjuvant therapy for breast 
cancer, annual mammography in women aged 40-59 years did not exceed mortality reduction 
achieved by physical examination [46]. The study of Autier et al. found that factors other 
than screening, amongst which breast cancer management, contributed to the reduction of 
breast cancer death risks [47]. A widely criticised and disputed study [48], mainly for its 
methodological considerations [49], concluded that, after the implementation of screening 
mammography, breast cancer mortality reduction was predominantly attributable to the 
improved systemic therapies. Modelling studies have also analysed the issue and reported 
that advances in systemic therapies for breast cancer have decreased the absolute benefit of 
regular screening but not the relative benefit due to their impact on survival from the disease 
[50], and estimated the contribution of adjuvant therapies to breast cancer mortality reduction 
to be ranging from 12% to 20.9%, while the reduction in the mortality rates attributable to 
screening was predicted to be from 7.5% to 22.7% [51, 52], concluding that adjuvant 
systemic therapy and screening reduced breast cancer mortality in similar amounts [52]. 
These recent developments suggested that systemic treatments could have synergistic and 
even competitive effects to regular screening on the mortality reduction from breast cancer. If 
the effects from systemic therapies are so considerable, then evaluations of lowering the 
intensity of mass screening by introducing longer screening intervals are warranted. In 
addition, costs of systemic therapies which increase more rapidly than effects need further 
consideration. 
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Current modelling studies were found to carry high risk of bias in their results due to the lack 
of transparency in the selection of sources for input data and assumptions, and the lack of 
external validation [53]. As compared to these recently reviewed simulation models [53] the 
SiMRiSc had the following advantages: external validation, systematically selected and 
evaluated independent sources for sampling of the input parameters, reporting on both 
expected benefits and harms of regular breast cancer screening. The systematic selection of 
input data and the external validation allow to compare and translate the results from our 
simulation to other Western countries. Another advantage of this analysis is that it included 
breast density variation as a function of age. Breast density is an important factor influencing 
negatively the sensitivity of mammography in younger ages [27] and thus the cost-
effectiveness of breast cancer screening. A limitation of the model is that DCIS was not 
included and thus disregarded from the validation and the cost-effectiveness analyses. 
Inclusion of DCIS, which accounted for nearly 20% of screen-detected tumours in the Dutch 
population in 2011 [39], could have an impact on the number of screen detected tumours and 
thus increase YOLS and cost-effectiveness, especially in the era of digital mammography. 
Another limitation is that the assumed tumour growth model does not account for tumour 
regression or growth stagnation; however, very slow growing tumours (on the edge of growth 
stagnation) are allowed in the model. In addition, the breast density parameter used in this 
model was derived from USA data, but it can be considered a good proxy for estimating 
breast density. However, as seen from the validation results these limitations did not seem to 
have large impact on the outcomes of the model. The validation of the SiMRiSc model was 
limited to the data available from the Dutch screening programme, which included screen 
detected tumours, tumour size distribution (of the screen detected tumours), number of 
interval cancers, number of false positive tests but not the distribution of breast density 
amongst the screened women nor size of the interval cancers. Breast density is a factor which 
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influences the sensitivity of mammography and the size of tumour is a predictor of survival 
and an argument in choosing a specific treatment. Our analysis focused only on quantitative 
outcomes and qualitative outcomes (such as quality of life) were not evaluated. It is known 
that regular breast cancer screening can have a negative impact on the quality of life in terms 
of pain from mammography, anxiety, and distress from false positive results in the short line, 
however, this has not been shown to affect generic health-related quality of life [54]. 
 
In conclusion, given the results from the simulation model, women could benefit from 
lowering the starting age of screening in terms of prevented cancer deaths due to the early 
diagnosis and treatment of the disease at reasonable additional costs and relatively low 
additional risks. Starting regular breast cancer screening earlier is also cost-effective. As the 
number of additional expected harms is relatively small in both alternative scenarios and the 
difference in ICERs is not large, introducing two additional screening rounds to the current 
biennial breast cancer screening in the Netherlands is justifiable from a cost-effectiveness and 
benefit-harms point of view. 
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Figure 1 
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Figure 2a. Tornado diagram for univariate sensitivity analyses 
 
Figure 2b. Tornado diagram for univariate sensitivity analyses 
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Table 1. Baseline estimations and 95% confidence intervals (CI) of input parameters 
 
 
 
  
Parameters Value (95% CI) 
Reference 
Tumour 
induction 
model 
Dose 
[mSv ]  
3 (1-5) 
[22] 
Probability 
of tumour 
induction 
[%] 
0.51 (0.28-0.83) 
Tumour 
growth 
model 
Tumour 
doubling 
time 
Days Geometric mean, 
log transformed 
Spread  
<50 years 80 4.38 (3.78-4.99) 0.43 [25] 
50-70 
years 
157 5.06 (4.80-5.32) 0.17 
>70 years 188 5.24 (4.79-5.69) 0.23 
Self-
detection 
model 
Self-
detection 
diameter 
[cm] 
Mean 3 (2.9-3.1) [39] 
standard deviation 0.65 (0.55-0.74) 
Cumulative 
incidence 
rate 
f [%] 24.0 (22.4-25.6) 
[24] 
m [years] 74.5 (72.3-76.7) 
s [years] 21.4 (19.6-23.2) 
Distribution 
of breast 
densities 
BI-RADS 
density 
score 
1 2 
 
3 
4 
 
<40 years 
[%] 
4.4 30.2 48.2 17.2 [27-29] 
40-50 
years 
[%] 
5.9 34.1 46.9 13.1 
50-60 
years 
[%] 
8.5 50.3 36.6 4.6 
60-70 
years 
[%] 
14.9 53.4 29.4 2.3 
>70 years 
[%] 
17.4  54.3 26.2 2.1 
Sensitivity [%] 
87 (75.2-
98.8) 
84 (80.1-
87.9) 
73 (54.8-
91.2) 
65 (34.0-
96.0) 
[30-38] 
Specificity [%] 96.5 (96.0 – 96.9) 
[26] 
Systematic error [%] 10 
Expert opinion 
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Table 2. Validation of the simulation results 
 
 simulated observed 
Number of screen detected tumours   
First screening round /age/   
50-54 284 259 (227-291) 
55-59 26 22 (12-32) 
60-64 18 20 (12-28) 
65-69 13 17(3-31) 
70-74 9 8(2-14) 
Subsequent screening rounds /age/   
50-54 728 405 (371-439) 
55-59 1052 710 (660-760) 
60-64 1083 800 (751-849) 
65-69 927 762 (711-813) 
70-74 775 734 (680-788) 
Tumour size distribution of screen-detected tumours   
<2cm 96.7% 78.3% 
2-5cm 3.2% 18.9% 
>5cm 0.1% 2.7% 
Number of interval cancers per 1000 screens 2.7 1* 
Number of false positive mammograms per 1000 screens 53.5 10.2 
* including DCIS 
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Table 3. Costs of screening, diagnosis and treatment of breast cancer in the Netherlands 
Procedure Costs (in Euro/2013) References 
Screening and diagnosis   
Mammogram 64 [39] 
Biopsy 176 [18] 
Treatment by tumour size   
Treatment <2cm 6438 [20, 40] 
Treatment 2-5cm 7128 [20, 40] 
Treatment >5cm 7701 [20, 40] 
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Table 4. Simulated outcomes, benefits and harms, costs and cost-effectiveness of breast cancer screening for 
two screening scenarios, biennial screening from 48 to 74 years of age, and biennial screening from 46 to 74 
years of age. All number are given for a cohort of 10,000 women 
 Scenario (start age-end age) 
 46-74 vs 48-74 48-74 vs 50-74 
Outcomes   
Number of screen detected tumours +3.3% (641) +4.0% (620) 
Detected tumours’ size distribution   
<2 cm +3.2% (610) +4.4% (591) 
2 – 5 cm +6.2% (29) -2.6% (27) 
≥5 cm +3% (1.4) -23.3% (1.3) 
Number of interval cancers +8.5% (271) +8.9% (250) 
Recall rates -2.8% -3.5% 
Expected benefits   
Number of tumour deaths prevented +4.2% (128) +5.6% (123) 
YOLS +3.7% (3,259) +5.6% (3,143) 
YOLS (discounted)  +4.5% (1182)*/ 
+0.5% (534)** 
+8.6% (1,131)*/ 
+5% (531)** 
Expected harms   
False positives +8.8% (4,085) +9.2% (3,754) 
Number of radiation-induced tumours +15.2% (39) +14.7% (33) 
Costs and cost-effectiveness   
Total costs/ million € +4.0% (17.4) +4.1% (16.7) 
Total costs (discounted)/ million € +4.8% (14.5)*/ 
+5.6% (12.6)** 
+4.8% (13.8)*/ 
+5.5% (11.9)** 
   
ICER 5.6/16.0*/27.1** 5.6/15.5*/26.0** 
ICERs are discounted according to: 
*  international (costs 3% and YOLS 3%) 
** Dutch guidelines (costs 1.5% and YOLS 4.5%) 
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